AEON Biopharma Overview
Latest P/E ratio for AEON Biopharma: -0.08 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.08
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for AEON is -0.08. That is below the sector sector average of 33.83. Investors often review this figure alongside AEON Biopharma's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AEON currently prints -0.08 for P/E ratio, while the sector average sits near 33.83. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at AEON Biopharma's growth, margins, and balance sheet.
A P/E ratio of -0.08 for AEON Biopharma is not 'good' or 'bad' on its own. Compare it with the peer average (33.83) and with AEON's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting AEON's P/E ratio (-0.08), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
